Form 4: Nurix Therapeutics Chief Legal Officer Christine Ring Reports Stock Transactions

Christine Ring, Chief Legal Officer of Nurix Therapeutics, reports the acquisition and disposal of common stock and restricted stock units to cover tax obligations.

Summary

• On October 30, 2024, Christine Ring, the Chief Legal Officer of Nurix Therapeutics, reported transactions involving the company's common stock and restricted stock units (RSUs).
• Ring acquired shares through the vesting of RSUs and simultaneously sold shares to cover tax withholding obligations.
• Specifically, 4,182 shares were sold at a weighted average price of $24.305, with prices ranging from $23.98 to $24.77.
• The transactions resulted in Ring holding 28,084 shares of common stock and various amounts of RSUs with different vesting schedules.
• These sales were mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a 'sell to cover' transaction and do not represent discretionary trades by the Reporting Person.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions by a company insider. It doesn't inherently convey positive or negative sentiment, as it primarily reflects routine compensation and tax-related activities.

Positives

• The vesting of RSUs indicates that performance milestones or time-based service requirements are being met.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders, as they primarily involve the insider's personal financial management related to equity compensation.

Key Dates